Cargando…

CXCR6 by increasing retention of memory CD8(+) T cells in the ovarian tumor microenvironment promotes immunosurveillance and control of ovarian cancer

PURPOSE: Resident memory CD8 T cells, owing to their ability to reside and persist in peripheral tissues, impart adaptive sentinel activity and amplify local immune response, and have beneficial implications for tumor surveillance and control. The current study aimed to clarify the less known chemot...

Descripción completa

Detalles Bibliográficos
Autores principales:	Muthuswamy, Ravikumar, McGray, AJ Robert, Battaglia, Sebastiano, He, Wenjun, Miliotto, Anthony, Eppolito, Cheryl, Matsuzaki, Junko, Takemasa, Tsuji, Koya, Richard, Chodon, Thinle, Lichty, Brian D, Shrikant, Protul, Odunsi, Kunle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Clinical/Translational Cancer Immunotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8491420/ https://www.ncbi.nlm.nih.gov/pubmed/34607898 http://dx.doi.org/10.1136/jitc-2021-003329

Ejemplares similares

Correction to: Tcf‑1 protects anti‑tumor TCR‑engineered CD8(+) T‑cells from GzmB mediated self‑destruction
por: Zangari, Brendan, et al.
Publicado: (2022)

Tcf-1 protects anti-tumor TCR-engineered CD8(+) T-cells from GzmB mediated self-destruction
por: Zangari, Brendan, et al.
Publicado: (2022)

LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8(+) T cell signaling and dampen antitumor immunity in a murine ovarian cancer model
por: Huang, Ruea-Yea, et al.
Publicado: (2015)

A rare population of tumor antigen-specific CD4(+)CD8(+) double-positive αβ T lymphocytes uniquely provide CD8-independent TCR genes for engineering therapeutic T cells
por: Matsuzaki, Junko, et al.
Publicado: (2019)

Oncolytic Maraba virus armed with tumor antigen boosts vaccine priming and reveals diverse therapeutic response patterns when combined with checkpoint blockade in ovarian cancer
por: McGray, A. J. Robert, et al.
Publicado: (2019)

Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer
por: Huang, Ruea-Yea, et al.
Publicado: (2016)

Efficient identification of neoantigen-specific T-cell responses in advanced human ovarian cancer
por: Liu, Song, et al.
Publicado: (2019)

Identification of Claudin 6-specific HLA class I- and HLA class II-restricted T cell receptors for cellular immunotherapy in ovarian cancer
por: Matsuzaki, Junko, et al.
Publicado: (2022)

A prime/boost vaccine platform efficiently identifies CD27 agonism and depletion of myeloid-derived suppressor cells as therapies that rationally combine with checkpoint blockade in ovarian cancer
por: McGray, A. J. R., et al.
Publicado: (2021)

Fidelity of human ovarian cancer patient-derived xenografts in a partially humanized mouse model for preclinical testing of immunotherapies
por: Odunsi, Adekunle, et al.
Publicado: (2020)

Genetic engineering of T cells with receptors from NY-ESO-1-specific tumor-recognizing CD4+ T cell as a novel approach for adoptive T cell therapy
por: Matsuzaki, Junko, et al.
Publicado: (2015)

WHSC1/NSD2 regulates immune infiltration in prostate cancer
por: Want, Muzamil Y, et al.
Publicado: (2021)

Expression and Immune Responses to MAGE Antigens Predict Survival in Epithelial Ovarian Cancer
por: Daudi, Sayeema, et al.
Publicado: (2014)

Tumor-infiltrating T lymphocyte clonality predicts prognosis in human ovarian cancer
por: Tsuji, Takemasa, et al.
Publicado: (2013)

GEN-1 in Combination with Neoadjuvant Chemotherapy for Patients with Advanced Epithelial Ovarian Cancer: A Phase I Dose-escalation Study
por: Thaker, Premal H., et al.
Publicado: (2021)

Direct tumor recognition by a human CD4(+) T-cell subset potently mediates tumor growth inhibition and orchestrates anti-tumor immune responses
por: Matsuzaki, Junko, et al.
Publicado: (2015)

Reprogramming antitumor immunity against chemoresistant ovarian cancer by a CXCR4 antagonist-armed viral oncotherapy
por: Komorowski, Marcin P, et al.
Publicado: (2016)

Split T Cell Tolerance against a Self/Tumor Antigen: Spontaneous CD4(+) but Not CD8(+) T Cell Responses against p53 in Cancer Patients and Healthy Donors
por: Tsuji, Takemasa, et al.
Publicado: (2011)

Clonality and antigen-specific responses shape the prognostic effects of tumor-infiltrating T cells in ovarian cancer
por: Tsuji, Takemasa, et al.
Publicado: (2020)

Metabolic features of cancer cells impact immunosurveillance
por: Joseph, Adrien, et al.
Publicado: (2021)

Neoantigens retention in patient derived xenograft models mediates autologous T cells activation in ovarian cancer
por: Want, Muzamil Yaqub, et al.
Publicado: (2019)

Immuno-stimultory/regulatory gene expression patterns in advanced ovarian cancer
por: Eng, Kevin H., et al.
Publicado: (2015)

IDO1 Expression in Ovarian Cancer Induces PD-1 in T Cells via Aryl Hydrocarbon Receptor Activation
por: Amobi-McCloud, Adaobi, et al.
Publicado: (2021)

Induction of cell death in ovarian cancer cells by doxorubicin and oncolytic vaccinia virus is associated with CREB3L1 activation
por: Mistarz, Anna, et al.
Publicado: (2021)

Reprogramming the tumor microenvironment leverages CD8(+) T cell responses to a shared tumor/self antigen in ovarian cancer
por: Mistarz, Anna, et al.
Publicado: (2023)

Enhanced immunotherapeutic profile of oncolytic virus-based cancer vaccination using cyclophosphamide preconditioning
por: Pol, Jonathan G, et al.
Publicado: (2020)

BiTE secretion by adoptively transferred stem-like T cells improves FRα+ ovarian cancer control
por: McGray, A J Robert, et al.
Publicado: (2023)

A novel cancer/testis antigen KP-OVA-52 identified by SEREX in human ovarian cancer is regulated by DNA methylation
por: KIM, KANG-MI, et al.
Publicado: (2012)

Cell therapies in ovarian cancer
por: Sarivalasis, Apostolos, et al.
Publicado: (2021)

High-dimensional analysis of the adenosine pathway in high-grade serous ovarian cancer
por: Bareche, Yacine, et al.
Publicado: (2021)

M2-like macrophages dictate clinically relevant immunosuppression in metastatic ovarian cancer
por: Hensler, Michal, et al.
Publicado: (2020)

Transcriptional analysis of multiple ovarian cancer cohorts reveals prognostic and immunomodulatory consequences of ERV expression
por: Natoli, Marina, et al.
Publicado: (2021)

In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models
por: Oba, Takaaki, et al.
Publicado: (2021)

ANKRD22 is a potential novel target for reversing the immunosuppressive effects of PMN-MDSCs in ovarian cancer
por: Chen, Huanhuan, et al.
Publicado: (2023)

Transmission of X-linked Ovarian Cancer: Characterization and Implications
por: Etter, John Lewis, et al.
Publicado: (2020)

Novel genetic variants in miR-191 gene and familial ovarian cancer
por: Shen, Jie, et al.
Publicado: (2010)

Activation of the COX2-PGE(2 )axis by immune effector cells results in the self-limiting nature of type-1 immunity in cancer tissues
por: Wong, Jeffrey L, et al.
Publicado: (2014)

Peripherally-driven myeloid NFkB and IFN/ISG responses predict malignancy risk, survival, and immunotherapy regime in ovarian cancer
por: Sprooten, Jenny, et al.
Publicado: (2021)

Siglec-9(+) tumor-associated macrophages delineate an immunosuppressive subset with therapeutic vulnerability in patients with high-grade serous ovarian cancer
por: Wang, Yiying, et al.
Publicado: (2023)

CXCL13 shapes immunoactive tumor microenvironment and enhances the efficacy of PD-1 checkpoint blockade in high-grade serous ovarian cancer
por: Yang, Moran, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_naidd9k57plo5mo943kj5g9o76